- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.
Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.
St. Jude shares deserve to be higher ahead of the merger with Abbott Labs. Here's why.
Political pressure is weighing on drug and medical device stocks including Abbott Labs and St. Jude, says Jim Cramer.